Meyers Primary Care Institute
Endocrine System Diseases | Female Urogenital Diseases and Pregnancy Complications | Health Services Administration | Health Services Research | Hormones, Hormone Substitutes, and Hormone Antagonists | Maternal and Child Health | Nutritional and Metabolic Diseases | Pharmaceutical Preparations | Women's Health
BACKGROUND: As the prevalence of diabetes mellitus increases in the population, the exposure to antidiabetic drugs (ADDs) during pregnancies is expected to grow, as has been seen over the last decade. The objective of this study was to estimate the prevalence of ADD use during pregnancy among women in the Mini-Sentinel Distributed Database (MSDD) who delivered a liveborn infant.
METHODS: We identified qualifying livebirth pregnancies among women aged 10 to 54 years in the MSDD from 2001 to 2013. ADD use was estimated using outpatient pharmacy dispensing claims and days-supplied among three cohorts: all livebirth pregnancies, pregnancies among women with pre-existing diabetes, and pregnancies among women without prior ADD use.
RESULTS: Among the 1.9 million pregnancies in the MSDD that resulted in a livebirth from 2001 to 2013, 4.4% were exposed to an ADD. Of the 15,606 pregnancies (0.8%) with pre-existing diabetes, 92.8% were also exposed during the pregnancy period. The most commonly used product in these pregnancies was insulin (75.6% of pregnancies). In contrast, in pregnancies of women without prior ADD use, the most commonly used products were glyburide and insulin, and most of these users were diagnosed with gestational diabetes.
CONCLUSIONS: Patterns of ADD use during pregnancy described here, along with changes in disease incidence and management, highlight the importance of continuing surveillance of ADD utilization patterns and examining the safety and effectiveness of these products in pregnancy.
Gestational diabetes, Glyburide, Insulin, Pregnancy
Rights and Permissions
© The Author(s). 2019 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
DOI of Published Version
BMC Pregnancy Childbirth. 2019 Nov 27;19(1):441. doi: 10.1186/s12884-019-2609-8. Link to article on publisher's site
BMC pregnancy and childbirth
Mott K, Reichman ME, Toh S, Kieswetter C, Haffenreffer K, Andrade SE. (2019). Use of Antidiabetic drugs during pregnancy among U.S. women with Livebirth deliveries in the Mini-Sentinel system. Open Access Articles. https://doi.org/10.1186/s12884-019-2609-8. Retrieved from https://escholarship.umassmed.edu/oapubs/4036
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Endocrine System Diseases Commons, Female Urogenital Diseases and Pregnancy Complications Commons, Health Services Administration Commons, Health Services Research Commons, Hormones, Hormone Substitutes, and Hormone Antagonists Commons, Maternal and Child Health Commons, Nutritional and Metabolic Diseases Commons, Pharmaceutical Preparations Commons, Women's Health Commons